The collaboration will explore the novel signaling pathways targeted by two of Jerini Ophthalmic’s leading drug candidates, JSM 6427, an integrin antagonist, and JPE 1375, an inhibitor of the complement cascade.
Under the terms of the agreement, Jerini Ophthalmic will finance full-time equivalents (FTE) and research costs over three years at the University College London (UCL) Institute of Ophthalmology and has certain exclusive rights over the intellectual property generated through the collaboration.
Anthony Adamis, CEO and president of Jerini Ophthalmic, said: “Our collaboration with David Shima and UCL gives Jerini Ophthalmic access to the best resources and expertise available in the field of ophthalmology. Working closely with the exceptional UCL research infrastructure will enable us to optimally develop and advance our ophthalmology drug candidates.”